MiOmo (MYO) Q1 2026: Recurring Patient Revenue Jumps to 49% as Channel Shift Accelerates

May 7, 2026 | By EarningsIQ Research

MiOmo’s Q1 results confirm a decisive pivot toward recurring patient sources, with nearly half of revenue now anchored in these lower-cost, higher-conversion channels. The company’s progress on payer contracts, international expansion, and operating leverage signals a business model in transition, with margin gains and pipeline growth laying groundwork for sustained acceleration. Investors should watch for continued MyoConnect adoption and international scaling as key drivers of the next growth wave.

Summary

  • Recurring Revenue Model Advances: Nearly half of revenue now comes from recurring patient sources, reducing acquisition costs and improving conversion.
  • International and Channel Mix Tailwind: German market traction and O&P channel growth are reshaping revenue composition and margin structure.
  • Pipeline and Payer Access Set Up 2026: Expanding referral base and payer contracts support visibility and potential for accelerated growth into next year.

Business Overview

MiOmo develops and commercializes the MyoPro, a powered arm orthosis that restores function for patients with upper limb paralysis, using non-invasive EMG sensors to amplify users’ own muscle signals. The company generates revenue through direct billing to payers, international and domestic O&P (orthotics and prosthetics) partners, and VA channels, with a growing focus on recurring referrals from rehab hospitals and clinics. Key segments include U.S. direct billing, international sales (notably Germany), and O&P partnerships, all supported by a payer contracting strategy that expands covered lives and increases market access.

Performance Analysis

Q1 2026 results highlight a business recalibrating for durable, margin-accretive growth. Revenue rose modestly, driven by a 9% increase in average selling price (ASP) due to favorable reimbursement updates and channel mix, despite slightly lower unit volumes. The recurring patient source strategy is gaining traction: these channels now account for 49% of revenue, up from 25% a year ago, with O&P revenue up 79% and international up 53% year over year. The German market delivered a record $2 million in Q1, underscoring international leverage.

Gross margin expanded by 100 basis points to 68.2%, reflecting higher ASPs and material cost reductions, partially offset by increased labor and travel for patient fittings. Operating expenses declined 1% year over year, as lower R&D and G&A offset higher sales and marketing investments. The transition away from advertising-driven direct patient acquisition is visible in improved adjusted EBITDA, a narrowing net loss, and reduced cash burn. Pipeline growth (up 13% year over year) and a rising share of intra-quarter revenue units signal improved velocity and demand visibility.

  • Channel Shift Impact: Direct billing now represents 71% of revenue, down from 79%, as recurring sources gain share and lower acquisition costs.
  • Lead Quality and Conversion: MyoConnect referrals are yielding higher-quality, better-qualified patients, improving both conversion and payer mix.
  • International Leverage: German statutory insurance and O&P partnerships are driving both revenue and ASP gains, with infrastructure investments set to scale further.

Operational discipline and strategic channel mix are reshaping the margin and growth profile, with the business positioned for more predictable, scalable expansion as payer access and referral networks deepen.

Executive Commentary

"Reimbursement by CMS in a new Medicare Part B benefit category with hip-fix codes for the MyoPro has opened access to a Medicare population of tens of millions, and remove the single largest historical barrier to adoption."

Paul Goudonis, Chief Executive Officer

"Revenue from recurring patient sources represented 49% of first quarter revenue, up from 25% in the prior year. As you can see, we have made significant progress in shifting toward recurring patient sources at a lower patient acquisition cost compared with advertising-driven direct patient revenues, which carry a much higher cost to acquire."

Dave Henry, Chief Financial Officer

Strategic Positioning

1. Recurring Patient Source Expansion

The MyoConnect program, launched mid-2025, is anchoring MiOmo’s pivot to referral-driven growth. By targeting rehab hospitals and O&P partners, the company is building a scalable, lower-cost funnel with higher conversion rates and improved patient quality. Over 150 rehab facilities are now referring patients, with ambitions to reach several hundred by year-end, laying the foundation for compounding growth in 2027 and beyond.

2. Payer Contracting and Market Access

National contracts—such as the arrangement with Elevance—have expanded covered lives from 9 million to 158 million in just two years. In-network status is driving higher authorization rates and reducing the need for time-consuming claim adjudication. The focus on Medicare Advantage and commercial contracts is mitigating macro headwinds in the payer landscape.

3. International Growth Engine

Germany has emerged as a high-potential, high-margin market, with favorable insurance rulings and a growing network of O&P partners. Record Q1 international revenue and ongoing expansion into additional European markets position MiOmo to leverage existing infrastructure for incremental growth.

4. Product and Technology Innovation

Recent launches—such as the MyoPro mobile app—are reducing material costs and enhancing user experience, while clinical trials at the University of Utah are expected to bolster reimbursement and clinical adoption. The MyoPro3 next-generation platform aims to support future software-driven innovation and functionality.

Key Considerations

This quarter marks a structural shift toward a more defensible, scalable business model, with execution against all four success pillars yielding tangible operational and financial benefits.

Key Considerations:

  • Channel Mix Evolution: The move toward recurring patient sources is lowering acquisition costs and smoothing revenue volatility, but requires sustained referral and partner engagement.
  • International Scale-Up: German market success demonstrates the playbook for other European entries, but reimbursement dynamics and resource allocation remain critical variables.
  • Margin Structure: Material cost reductions from product innovation are offsetting labor and travel inflation, but sequential margin variability from channel mix remains a watchpoint.
  • Payer Landscape: Growing in-network contracts are reducing claims friction, but macro uncertainty in Medicare Advantage requires ongoing vigilance and adaptation.

Risks

Execution risk remains around referral channel ramp, as the MyoConnect program must continue to scale and produce same-store sales growth to sustain the model. International expansion is subject to reimbursement and regulatory complexity, with Germany’s success not guaranteed to translate elsewhere. Medicare Advantage macro headwinds and channel mix shifts could pressure ASP and margins if not offset by volume and operational leverage. Investors should monitor pipeline conversion rates and payer authorization trends closely.

Forward Outlook

For Q2 2026, MiOmo guided to:

  • Revenue of $10.3 to $10.8 million (up 7% to 12% YoY, up 2% to 7% sequentially)
  • Gross margin higher YoY but lower sequentially, driven by channel mix

For full-year 2026, management reiterated guidance:

  • Revenue of $43 million to $46 million
  • Operating expense growth limited to half the rate of revenue growth

Management emphasized:

  • Marketing investments will increase in Q2 and Q3 to build backlog for later quarters
  • MyoConnect referral growth and payer contract execution are key swing factors for hitting the upper end of guidance

Takeaways

MiOmo’s first quarter demonstrates the early payoff of a deliberate channel and payer strategy shift, with recurring referrals and international traction driving both margin and pipeline improvement.

  • Channel Transformation: Recurring patient sources are materially reducing acquisition costs and improving patient quality, but require continued partner engagement and operational discipline.
  • Margin and Pipeline Momentum: ASP gains, cost reductions, and a growing qualified pipeline provide visibility into margin expansion and future revenue acceleration.
  • Watch Referral and International Scale: Sustained MyoConnect adoption and further European expansion will determine if the current trajectory can be maintained or accelerated into 2027.

Conclusion

MiOmo’s Q1 2026 results validate its pivot to a recurring, referral-driven model, with international and payer contracting strategies unlocking new growth levers. The company’s execution against its four pillars positions it for improved visibility, margin, and scale, but ongoing delivery on referral and international initiatives will be crucial to sustaining momentum.

Industry Read-Through

MiOmo’s success in converting to a recurring referral model and expanding payer access offers a roadmap for other medtech and device companies facing reimbursement and acquisition cost headwinds. The German market’s favorable reimbursement climate highlights the value of targeting statutory insurance regimes for international growth. O&P channel partnerships and digital lead quality improvements reflect broader industry trends toward channel diversification and margin focus. Companies reliant on advertising-driven patient acquisition may face increasing pressure to pivot toward lower-cost, higher-conversion referral sources, especially as payers demand more clinical evidence and value-based outcomes.

MYO Healthcare Medical Devices Recurring Revenue International Payer Contracts Orthotics